Phase III MARIANNE Study Fails To Improve PFS with Kadcyla in HER2-Positive Breast Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Top-line results of the phase III MARIANNE study evaluated three HER2-targeted regimens—Kadcyla (ado-trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy—in people with previously untreated advanced HER2-positive breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login